Cytokine signaling--regulation of the immune response in normal and critically ill states.
暂无分享,去创建一个
[1] P. Blackshear,et al. Necrosis Factor Alpha Mrna Deadenylation and Destabilization of Tumor Au-rich Elements and Promotes the Evidence That Tristetraprolin Binds To , 1999 .
[2] G. Kollias,et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. , 1999, Immunity.
[3] I. Kushner,et al. Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.
[4] I. Chaudry,et al. Severe depression of host immune functions following closed-bone fracture, soft-tissue trauma, and hemorrhagic shock. , 1998, Critical care medicine.
[5] R. Huber,et al. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] C. Dinarello,et al. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. , 1997, Chest.
[7] G. Zimmerman,et al. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. , 1997, The Journal of clinical investigation.
[8] J. Mege,et al. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. , 1997, Critical care medicine.
[9] J. Lederer,et al. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. , 1997, Annals of surgery.
[10] U. Steckholzer,et al. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. , 1997, The Journal of trauma.
[11] R. Kamen,et al. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN- γ production , 1997, Nature.
[12] J. Kremer,et al. Inhibition of the Defense System Stimulating Interleukin-12 Interferon-γ Pathway During Critical Illness , 1997 .
[13] K. Asadullah,et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. , 1997, Archives of internal medicine.
[14] M. Lambert,et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.
[15] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[16] R. Flavell,et al. Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. , 1997, Journal of immunology.
[17] D. Klinman,et al. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. , 1996, Journal of immunology.
[18] T. Standiford,et al. Balance of inflammatory cytokines related to severity and mortality of murine sepsis , 1996, Infection and immunity.
[19] H. Okamura,et al. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. , 1996, Cellular immunology.
[20] H. Okamura,et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. , 1996, Journal of immunology.
[21] R. Bone,et al. Sir Isaac Newton, sepsis, SIRS, and CARS. , 1996, Critical care medicine.
[22] M. Cuesta,et al. Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. , 1996, Blood.
[23] R. Locksley,et al. The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.
[24] S. Beaucage,et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Dipiro,et al. Interleukin-10 is associated with the development of sepsis in trauma patients. , 1996, The Journal of trauma.
[26] C. Dinarello,et al. Biologic basis for interleukin-1 in disease. , 1996, Blood.
[27] R. Black,et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. , 1995, Journal of immunology.
[28] G. Yancopoulos,et al. Designer Cytokines: Targeting Actions to Cells of Choice , 1995, Science.
[29] John A. Mannick,et al. Major Injury Leads to Predominance of the T Helper‐2 Lymphocyte Phenotype and Diminished Interleukin‐12 Production Associated with Decreased Resistance to Infection , 1995, Annals of surgery.
[30] S. Akira,et al. Interleukin-6 family of cytokines and gp130. , 1995, Blood.
[31] F. Schildberg,et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. , 1995, Blood.
[32] R. Black,et al. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes , 1995, The Journal of experimental medicine.
[33] S. Dower,et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. , 1994, Journal of immunology.
[34] C. Biron. Cytokines in the generation of immune responses to, and resolution of, virus infection. , 1994, Current opinion in immunology.
[35] E. Maggi,et al. Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[36] A. Mantovani,et al. The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor , 1994, The Journal of experimental medicine.
[37] P. Barie,et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. , 1994, Journal of the American College of Surgeons.
[38] J. Jensenius,et al. Collectins: collagenous C-type lectins of the innate immune defense system. , 1994, Immunology today.
[39] D. Fearon,et al. Innate immunity: 50 ways to kill a microbe. , 1994, Current opinion in immunology.
[40] R. Bone,et al. Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.
[41] L. Tartaglia,et al. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.
[42] A. Drost,et al. Plasma cytokines following thermal injury and their relationship with patient mortality, burn size, and time postburn. , 1993, The Journal of trauma.
[43] A. Mantovani,et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.
[44] M. Gayle,et al. Interleukin 1 signaling occurs exclusively via the type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[45] B. Barton,et al. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model , 1993, Infection and immunity.
[46] L. Moldawer,et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[47] I. Chaudry,et al. Sepsis induces an early increased spontaneous release of hepatocellular stimulatory factor (interleukin-6) by Kupffer cells in both endotoxin tolerant and intolerant mice. , 1992, The Journal of surgical research.
[48] I. Chaudry,et al. Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukins-1 and -6 and tumor necrosis factor). , 1992, Circulatory shock.
[49] D. Wallach,et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.
[50] Y. Vodovotz,et al. Macrophage deactivation by interleukin 10 , 1991, The Journal of experimental medicine.
[51] C. Dinarello,et al. Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells , 1991, Brain Research.
[52] T. Mosmann,et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.
[53] L. Gooding,et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.
[54] R. Ulevitch,et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.
[55] J. Vilček,et al. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. , 1989, Journal of immunology.
[56] K. Tracey,et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.
[57] L. Moldawer,et al. Cachectin/tumor necrosis factor‐α alters red blood cell kinetics and induces anemia in vivo , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] P. Brandtzaeg,et al. Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .
[59] A. Waage,et al. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.
[60] T. Ikejima,et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.
[61] K. Tracey,et al. Cytokine appearance in human endotoxemia and primate bacteremia. , 1988, Surgery, gynecology & obstetrics.
[62] A. Waage,et al. ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.
[63] A. Forrest,et al. Letter: Procaine and malignant hyperthermia. , 1974, Lancet.
[64] G. Fantuzzi,et al. Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). , 1999, Journal of clinical immunology.
[65] C. Dinarello. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. , 1999, The Journal of allergy and clinical immunology.
[66] S. Calvano,et al. Trauma-induced alterations in macrophage function. , 1998, Surgery.
[67] J. Kremer,et al. Inhibition of the defense system stimulating interleukin-12 interferon-gamma pathway during critical Illness. , 1997, Blood.
[68] K. Asadullah,et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. , 1997, Nature medicine.
[69] R. Kamen,et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. , 1997, Nature.
[70] G. Trinchieri. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.
[71] R. Ulevitch,et al. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. , 1995, Annual review of immunology.
[72] K. Tracey,et al. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.
[73] H. Tilg,et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.
[74] M. Farrar,et al. The molecular cell biology of interferon-gamma and its receptor. , 1993, Annual review of immunology.
[75] P. Barie,et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. , 1990, Surgery, gynecology & obstetrics.
[76] S. Akira,et al. Biological and clinical aspects of interleukin 6. , 1990, Immunology today.
[77] R. Coffman,et al. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.
[78] L. Moldawer,et al. Cachectin: its impact on metabolism and nutritional status. , 1988, Annual review of nutrition.
[79] P. Néve,et al. Interleukin 2 , 1987, Acta clinica Belgica.